世界各国干细胞治疗相关政策与规划分析

随着生物技术的迅速发展,干细胞（stem cell）作为具有复制和多向分化功能的集体起源细胞,对人体发育、衰老和疾病的治疗有着巨大的作用,受到世界各国的普遍关注。自从20世纪末美国Science（《科学》）杂志两年连续两次将干细胞生物学和干细胞生物工程评为世界十大科学成就之首以来,干细胞领域就持续成为国内外医学和生物学研究的热点。人们期待着干细胞技术能很快产业化,形成治疗产品,用来重建和修复病变或衰老的组织器官。     

肿瘤干细胞研究进展及临床应用前景

肿瘤干细胞是肿瘤中具有自我更新能力和分化潜能,能产生异质性细胞的细胞。我们简要阐述了肿瘤干细胞存在的证据、分离技术及来源,并对以肿瘤干细胞为靶标的肿瘤治疗途径、临床应用前景和问题进行了综述。     

对比不同类型干细胞对于缺血性脑卒中治疗的研究进展

成人中枢神经系统存在着一定量的神经干细胞,其具有两大关键能力;自我更新和多向分化潜能。缺血性脑卒中是一种由于由脑血流的缺失或减少引起的脑动脉闭塞,进而导致脑组织梗死的脑血管疾病。虽然对于脑损伤的药物治疗已经取得了一定的成果,但目前以干细胞为基础的治疗方法仍成为了研究热点。无论是内源性神经干细胞还是外源性神经干细胞移植均可在脑损伤后向远端损伤区迁移并分化成新的神经细胞,从而在中枢神经系统疾病尤其是脑梗死后进行组织修复和功能恢复。因此在这篇综述中,我们主要探讨不同类型的干细胞对脑梗死介导的脑损伤的应用潜能,对比不同类型干细胞对缺血性脑卒中的治疗优缺点。     

骨髓间充质干细胞在大鼠实验中的移植途径及比较

骨髓间充质干细胞是具有自我更新能力和分化潜能的一类成体干细胞,经过局部微环境的诱导,可在体内外进行扩展,到晚期可分化成为多种细胞系。当组织受损伤时,可迅速到达损伤部位,分化为特异的组织细胞,参与组织修复。骨髓间充质干细胞这种惊人的分化及组织修复能力,为治疗退行性疾病和器官损伤性疾病提供广阔前景,故成为科研热点。国内外相关实验研究多以大鼠为动物模型,而骨髓间充质干细胞如何进入大鼠体内并定植,是实验成功的重要前提。因此如何找到最合适、最安全的移植途径将骨髓间充质干细胞有效地移植进入大鼠疾病模型体内的受损区域,是研究者关心的重点。本文就目前骨髓间充质干细胞在大鼠实验中不同移植途径进行综述,并比较各种途径的优缺点,希望能对临床科研工作提供参考,并期待能有更成熟的移植手段来推动骨髓间充质干细胞实验研究的进展。     

乳腺癌干细胞和乳腺癌

肿瘤干细胞既包含干细胞的特性也包含肿瘤细胞的特性。乳腺癌起源于乳腺癌干细胞的说法能够合理地解释乳腺癌的不均一性及其治疗后的复发,这些变异的干细胞可能作为肿瘤预防策略的靶标。而且,由于乳腺癌干细胞能够抵抗辐射治疗和化学治疗,所以要想更好地治疗乳腺癌就需要寻找针对这些干细胞的靶标。我们综述了乳腺癌干细胞的发现、富集和分离、相关的信号途径,以及在乳腺癌治疗中的应用。     

灵长类干细胞在基础科学与应用研究中的机遇与展望

以干细胞治疗为核心的再生医学为人类退行性和损伤性的重大疾病治疗提供了希望。然而,干细胞应用于人之前,一些重大的科学问题和治疗的安全性、有效性还没有得到有效的回答和验证。由于啮齿类动物在遗传、代谢和生理表型等方面与人存在较大差异,因此其研究结果较难转化到人上。非人灵长类(NHP)与人高度相似,因此,利用NHP模型可以回答和解决啮齿类动物无法回答的问题,从而解决干细胞基础科学和再生医学技术瓶颈问题。该文首先总结了在NHP模型上需解决的干细胞重大科学问题和技术瓶颈,如干细胞的多能性、治疗的安全性和效率等。其次,评述了一些新技术的出现将加速灵长类干细胞研究和应用。结合NHP模型,这些技术将促进干细胞在基础科学和临床治疗中的应用研究。最后,建议将干细胞的先进技术应用于NHP模型,这将极大促进干细胞关键科学问题的回答和技术瓶颈的解决。     

干细胞治疗：从研发到应用

干细胞治疗的应用既离不开基础研究的发展和技术的不断进步,也离不开科技政策的支持、生产工艺的进步、临床研究的发展,以及企业对干细胞相关产品的开发。本文从管理政策、生产技术、临床研究、产品开发等多个角度,就与干细胞治疗相关的研究现状和前景进行评述。     

干细胞巢研究进展

干细胞巢即干细胞周围的微环境构成,一般包括干细胞的相邻细胞、粘附分子及基质等,但不同的干细胞有不同的巢结构。干细胞巢通过不同信号途径调控着干细胞的行为,使干细胞的自我更新和分化处于平衡状态。根据近年来有关干细胞巢的研究,本文从果蝇生殖系干细胞巢、哺乳动物造血干细胞巢、肠干细胞巢、毛囊表皮干细胞巢和神经干细胞巢等五个系统分别综述了干细胞巢的构成及其对干细胞的调节作用,探讨了干细胞巢作用于干细胞的内在机制。     

干细胞治疗糖尿病的研究进展

随着糖尿病的发病率升高,世界各国科学家积极地寻找治疗糖尿病的有效方法.干细胞是近年来的研究热点之一,很多科学家着眼于应用干细胞治疗糖尿病,并取得了显著的成效.本文综合近些年来各国科学家的研究成果,从胚胎干细胞、胰腺干细胞、骨髓干细胞、骨髓造血干细胞等4个方面介绍当前的研究情况,同时时比4种干细胞治疗糖尿病的优缺点.     

利用精原干细胞法生产转基因动物的研究进展

综述了利用精原干细胞生产转基因动物的发展历程、方法以及最新研究进展.重点从精原干细胞移植法和曲细精管微注射法两个方面,系统分析了利用精原干细胞生产转基因动物的优缺点,以及当前存在的问题.     

干细胞和产前治疗

干细胞特殊的生物性质为产前治疗的研究和应用带来了新的希望。近年来,借助干细胞进行的产前治疗的基础研究进展迅速,为早日在临床广泛开展产前治疗提供了大量有益的参考和指导。本文就这方面的研究进展作一综述。 Stem Cells and Prenatal Therapy WANG Mo-lin,HUANG Shu-zhen Shanghai Institute of Medical Genetics,Shanghai Children Hospital,Shanghai 200040,China Abstract:The special biological properties of stem cells bring us new hope for the research and application of prenatal therapy.The basic reseach of prenatal therapy utilizing stem cells developed quickly,providing reference and direction for clinical therapy.This review is mainly related to the progress in this field in recent years. Key words：stem cell;prenatal therapy     

The prospect of pluripotent stem cell-based therapy

Human embryonic stem cells (hESC) are able to maintain pluripotency in culture, to proliferate indefinitely and to differentiate into all somatic cell types. Due to these unique properties, hESC may become an exceptional source of tissues for transplantation and have a great potential for the therapy of incurable diseases. Here, we review new developments in the area of embryonic stem cells and discuss major challenges — standardization of protocols for cell derivation and cultivation, identification of specific molecular markers, development of new approaches for directed differentiation, etc. — which remain to be settled, prior to safe and successful clinical application of stem cells. We appraise several potential approaches in hESC-based therapy including derivation of autologous cells via therapeutic cloning (1), generation of immune tolerance to allogenic donor cells via hematopoetic chimerism (2), and development of the banks of hESC lines compatible with the main antigens and exhibiting equivalent pluripotency (3). In addition, we discuss briefly induced pluripotent cells, which are derived via genetic modification of autologous somatic cells and are analogous to ESC. Our analysis demonstrates that uncontrollable differentiation in vivo and teratogenic potential of hESC are critical limitations of their application in clinical practice. Therefore, the major approach in hESC therapy is derivation of a specific differentiated progeny, which has lower proliferative potential and immune privilege, yet poses fewer risks for organism. The review demonstrates that cell therapy is far more complex and resource-consuming process as compared with drug-based medicine and consequently pluripotent stem cell biology and technology still requires further investigation and development before these cells can be used in clinical practice.     

Prospect of mesenchymal stem cells in therapy of osteoporosis: A review

Osteoporosis is a systemic skeletal disease associated with reduced bone strong point that results in raised fracture risk, with decreased bone strength, leading to reduced bone mineral density and poor bone quality. It is the most common in older females but some men are also at high risk. Although considered as a predictable result of aging, it is can be avoidable and treatable. The existing treatment of osteoporosis mainly contains antiresorptive and anabolic agents. In spite of these improvements, concerns around unusual side-effects of antiresorptive drugs, and the lack of perfect confirmation in maintenance of their long-standing effectiveness is bring about many patients not receiving these drugs. Over the years, the stem cell-based therapy has attained substantial clinical consideration because of its potential to treat numerous diseases. The stem cell therapy has been recommended as a probable therapeutic approach for patients with osteoporosis. Even though the concept of stem cell-based therapy for osteoporosis has caught substantial attention, no clinical trial has been published on humans. The cell studies based on osteoporosis are primarily focused on osteoclastic activity and bone resorption procedures. Earlier, it was on osteoblastogenesis and in recent times, on the differentiation probable of mesenchymal stem cells. In this review, we have summarized the therapeutic role of stem cell-based strategy in osteoporosis.     

间充质干细胞的细胞成像技术比较与应用

间充质干细胞是一类具有强大增殖、多向分化潜能和免疫调节能力的多功能细胞,研究显示间充质干细胞移植可能治疗多种难治性疾病,例如帕金森病、脊髓损伤以及肿瘤等。但是,人们对移植后的细胞在宿主内的存活、分布、增殖、分化、免疫排斥反应以及成瘤特性等问题尚不清楚,所以许多疾病经过细胞移植治疗后的进展及转归情况仍难以获得确切的科学证据。而细胞成像技术(包括放射性核素成像、超声成像、磁共振成像以及光学成像)可以在体外或者体内实现对间充质干细胞实时、无创的示踪,在以间充质干细胞为研究基础的细胞移植治疗和细胞组织再生的医学领域里有着巨大的应用潜力。该文综述近十年来细胞成像技术应用于示踪间充质干细胞移植疗法的研究进展,旨在比较当下多种热门细胞成像技术的优劣,进而找寻更合适的干细胞示踪策略,为干细胞移植治疗的基础和临床研究提供进一步的理论证据支持和研究思路。     

应用骨髓干细胞治疗肝硬化研究进展

随着干细胞研究的深入和技术的发展,再生医学的干细胞疗法治疗肝脏疾病已成为研究热点。骨髓来源造血干细胞和间充质干细胞等在肝脏疾病治疗方面有巨大潜力。骨髓干细胞参与肝纤维化与肝硬化修复主要包括迁移、归巢与转化等过程,并需要多种细胞因子和趋化因子的协同作用促进肝细胞再生与减轻肝纤维化。本文拟对骨髓干细胞治疗肝硬化的最新研究进展进行综述。     

肿瘤干细胞鉴定方法

肿瘤干细胞假说是近年来提出的关于肿瘤发生的新理论,该理论认为肿瘤组织中仅有一小部分细胞可以产生肿瘤并且维持肿瘤生长。在体内外如何鉴定这种具有启动以及保持肿瘤生长的细胞类型,成为肿瘤基础及应用研究的关键问题。目前已经在白血病、乳腺癌、神经胶质瘤等肿瘤中成功鉴定并分离出肿瘤干细胞,这对于肿瘤的临床治疗具有重要意义。本文主要从肿瘤干细胞的鉴定及其在临床研究中的应用等方面进行综述。     

中国细胞重编程和多能干细胞研究进展

近几十年是干细胞领域飞速发展的重要时期。随着中国经济实力的发展壮大,科研实力也在稳步增强,干细胞研究领域达到了国际并跑甚至领跑的水平。本文从体细胞核移植、诱导多能干细胞、单倍体多能干细胞和胚胎早期发育研究4个方面,对中国细胞重编程和干细胞领域的研究进展进行了历史性回顾,总结了中国科学家在相关领域所取得的重要科研成果。随着单细胞测序技术的发展,各种发育过程将实现更为深入的解读,干细胞的临床应用在中国也会大放异彩。     

Teeth-derived stem cells: A source for cell therapy

Cell therapy is one of the important therapeutic approaches in the treatment of many diseases such as cancer, degenerative diseases, and cardiovascular diseases. Among various cell types, which could be used as cell therapies, stem cell therapy has emerged as powerful tools in the treatment of several diseases. Multipotent stem cells are one of the main classes of stem cells that could originate from different parts of the body such as bone marrow, adipose, placenta, and tooth. Among several types of multipotent stem cells, tooth-derived stem cells (TDSCs) are associated with special properties such as accessible, easy isolation, and low invasive, which have introduced them as a good source for using in the treatment of several diseases such as neural injuries, liver fibrosis, and Cohrn’s disease. Here, we provided an overview of TDSCs particular stem cells from human exfoliated deciduous teeth and clinical application of them. Moreover, we highlighted molecular mechanisms involved in the regulation of dental stem cells fate.     

Human parthenogenetic embryonic stem cells: one potential resource for cell therapy

Pluripotent stem cells derived from somatic cells through such processes as nuclear transfer or induced pluripotent stem (iPS) cells present an important model for biomedical research and provide potential resources for cell replacement therapies. However, the overall efficiency of the conversional nuclear transfer is very low and the safety issue remains a major concern for iPS cells. Embryonic stem cells (ESCs) generated from parthenogenetic embryos are one attractive alternative as a source of histocompatible cells and tissues for cell therapy. Recent studies on human parthenogenetic embryonic stem cells (hPG ESCs) have revealed that these ESCs are very similar to the hESCs derived from IVF or in vivo produced blastocysts in gene expression and other characteristics, but full differentiation and development potential of these hPG ESCs have to be further investigated before clinical research and therapeutic interventions. To generate various pluripotent stem cells, diverse reprogramming techniques and approaches will be developed and integrated. This may help elucidate the fundamental mechanisms underlying reprogramming and stem cell biology, and ultimately benefit cell therapy and regenerative medicine. Supported by the National High Technology Research and Development Program of China (Grant No. 2006AA02A101).     

Current focus of stem cell application in retinal repair

The relevance of retinal diseases, both in society’s economy and in the quality of people’s life who suffer with them, has made stem cell therapy an interesting topic forresearch. Embryonic stem cells(ESCs), induced pluripotent stem cells(i PSCs) and adipose derived mesenchymal stem cells(ADMSCs) are the focus in current endeavors as a source of different retinal cells, such as photoreceptors and retinal pigment epithelial cells. The aim is to apply them for cell replacement as an option for treating retinal diseases which so far are untreatable in their advanced stage. ESCs, despite the great potential for differentiation, have the dangerous risk of teratoma formation as well as ethical issues, which must be resolved before starting a clinical trial. i PSCs, like ESCs, are able to differentiate in to several types of retinal cells. However, the process to get them for personalized cell therapy has a high cost in terms of time and money. Researchers are working to resolve this since i PSCs seem to be a realistic option for treating retinal diseases. ADMSCs have the advantage that the procedures to obtain them are easier. Despite advancements in stem cell application, there are still several challenges that need to be overcome before transferring the research results to clinical application. This paper reviews recent research achievements of the applications of these three types of stem cells as well as clinical trials currently based on them.